AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03817684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01263119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10-mg warfarin oral dose
Study NCT01263119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: 18-mg LY2216684 oral dose
Study NCT03997032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocufolin
Description: Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
Study NCT02138825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
Study NCT02138825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
Study NCT02138825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
Study NCT02683902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
Study NCT02683902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
Study NCT02683902 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hypocaloric diet
Description: A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
Study NCT01182389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Review of ICD programming to ensure that detection and therapy will occur appropriately
Study NCT01611129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based counseling
Description: Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
Study NCT01611129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based counseling
Description: Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
Study NCT01981278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 250-mg TRF tablet
Description: Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
Study NCT01981278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER 250-mg PR2 tablet
Description: Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
Study NCT01894477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant
Study NCT02304913 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Study NCT02683902 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
Study NCT02176915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group program
Study NCT02176915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Print Materials
Study NCT04524988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Simulation Training
Description: All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
Study NCT04524988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Simulation Training
Description: All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
Study NCT04925141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib Tablets
Description: Tyrosine Kinase Inhibitor (TKI)
Study NCT06446570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab,Tremelimumab
Description: Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Study NCT03481439 — intervention group
Intervention type: OTHER
Intervention: Collection of a Pharmaceutical intervention
Description: collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
Study NCT01100112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
Study NCT02304913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary recommendations
Study NCT01301716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral escalating dose
Study NCT01301716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT04870866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide ribonucleoside
Description: Two year intervention
Study NCT02012517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged antibiotic treatment
Study NCT02012517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short antibiotic course (standard of care)
Study NCT02660229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride
Description: Oxycodone injection
Study NCT02660229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulphate
Description: Morphine sulphate injection
Study NCT03618537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.
Study NCT03618537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.
Study NCT00842621 — intervention group
Intervention type: PROCEDURE
Intervention: Clinical Evaluations
Description: All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
Study NCT00842621 — intervention group
Intervention type: OTHER
Intervention: Laboratory Studies
Description: Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin
Study NCT01892566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: See arm description
Study NCT00309218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
Study NCT00309218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
Study NCT03479983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AMX160
Description: 500 mg Phyllanthus emblica L. fresh fruit extract capsules
Study NCT03479983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg roasted rice powder in visually identical capsules
Study NCT01517984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (CNI) Withdrawal
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.
Study NCT01517984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Immunosuppressive Therapy
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Study NCT01517984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Immunosuppressive Therapy
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Study NCT01658046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
Study NCT01658046 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Endurance training
Description: Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
Study NCT01658046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
Study NCT01658046 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quadriceps strength training
Description: Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
Study NCT01658046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps strength training
Description: Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
Study NCT01092884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polypodium leucotomos extract
Description: 240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
Study NCT01092884 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This placebo capsule will be taken orally three times daily
Study NCT00992550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette
Study NCT00992550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hookah
Study NCT03800550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline tablet will be administered, orally.
Study NCT01301716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose
Study NCT01301716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: intravenous repeating dose
Study NCT01894477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Intravenously administered Fludarabine Phosphate
Study NCT01894477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT01894477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01894477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Intravenously administered Treosulfan
Study NCT01894477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT04274660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DWELL (Diabetes and WELLbeing) Programme
Description: 12-week psychoeducational programme
Study NCT02504268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study NCT02504268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT03800550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablet will be administered, orally.
Study NCT03773809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D capsule
Description: The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
Study NCT03773809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of placebo
Study NCT01301716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose
Study NCT03526263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric mucosal devitalization
Description: During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
Study NCT01912235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-15N glutamine
Description: Glutamine with N15 isotope tracer
Study NCT01912235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15N2 arginine and 15N proline
Description: Arginine and Proline isotope tracers
Study NCT01912235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-13C glutamine
Description: Glutamine carbon isotope tracer
Study NCT01301716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: intravenous repeating dose
Study NCT00502736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bondronat]
Description: 6mg iv on days 1-3
Study NCT01475721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 100/50mcg
Description: fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
Study NCT01475721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 250/50mcg
Description: fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
Study NCT00651105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT01475721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAIR 500/50mcg
Description: fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
Study NCT01475721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 100mcg
Description: fluticasone propionate (100) twice daily (AM and PM) for 6 months
Study NCT01475721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT 250mcg
Description: fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
Study NCT00443092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprietary cherry juice blend (food)
Description: 2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
Study NCT00443092 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control juice (kool aid blend)
Description: 2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
Study NCT03985904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART THERAPY
Description: ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
Study NCT04079946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Mesocolic Excision with Central Vessel Ligation
Description: sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
Study NCT04079946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery of cancer colon
Description: removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
Study NCT03424200 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine care
Description: Participants will receive routine care
Study NCT03424200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coaching plus routine care
Description: Participants will receive coaching plus routine care
Study NCT02158273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 145 mg/day, oral pill, 9 days
Study NCT02158273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRICOR (fenofibrate)
Description: 145 mg/day, oral pill, 9 days
Study NCT01622231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: 55 mcg/day, intranasal, 12 weeks
Study NCT00726869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab (HuLuc63)
Description: Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
Study NCT00651105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03733522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration